Charles River Laboratories (CRL) Baird Global Healthcare Conference 2025 summary

Strategic review and portfolio analysis

• A strategic review is underway with urgency, focusing on unlocking value and assessing the entire portfolio for potential changes.

• The process is collaborative, involving a refreshed board and a large shareholder, aiming for objectivity and professionalism.

• No specific timeline for conclusions, but updates will be provided as soon as a decision is reached.

• The review considers connectivity among business segments and how to maximize value for the whole organization.

DSA segment and market dynamics

• Book-to-bill ratios were above one in Q1 but dropped below one in Q2, expected to remain constant for the rest of the year.

• Small biotech demand is challenged by limited access to capital, impacting growth and bookings.

• Pent-up demand exists among small biotechs, but recovery depends on improved capital markets.

• Hiring has resumed to meet anticipated workload, with about 100 new positions added to support current and incoming projects.

• Cancellations fluctuate but show no structural shift in client demand or behavior.

Research models and CRADL business

• Research models business remains stable despite regulatory and funding uncertainties, with government and academic contracts forming a small portion of revenue.

• NIH contract reductions have not significantly impacted operations, and long-term contracts provide stability.

• CRADL (Accelerated Development Labs) growth has slowed due to biotech funding constraints but remains a high-margin, strategically important business.

• The business serves both small and large clients, offering flexibility and cost management.